News

Onc.AI Receives $2 Million Grant to Enhance Cancer Treatment AI

Onc.AI Receives $2 Million Grant to Enhance Cancer Treatment AI

Onc.AI Awarded Significant Grant for Cancer AI Development

In an exciting advancement for oncology, Onc.AI, a pioneer in digital health, announced a substantial $2 million grant awarded by the National Cancer Institute (NCI). This funding aims to propel the development of their innovative AI-driven clinical decision support system specifically tailored for non-small cell lung cancer (NSCLC). The focus of this grant is to further clinical validation and enhancement of Onc.AI’s groundbreaking imaging-AI software.

Transforming Clinical Decision-Making in NSCLC

This grant will facilitate a comprehensive multi-institutional, prospective clinical study to evaluate NSCLC patients. Onc.AI's AI-based clinical decision support system has shown considerable promise in assisting oncologists to determine a metastatic NSCLC patient’s chances of achieving progression-free survival. This initiative builds on the previous successes the company experienced, particularly the impressive outcomes presented at the 2024 American Society of Clinical Oncology (ASCO) meeting.

At this prestigious event, Onc.AI showcased their ability to provide adjunctive support through a single pre-treatment CT scan, demonstrating a leap forward in how medical professionals can utilize imaging data for better outcomes.

Innovative Technology in Oncology

Onc.AI employs cutting-edge deep learning techniques to analyze and quantify complex imaging features. This analysis reveals critical insights regarding a patient’s likelihood of responding to immune checkpoint inhibitor (ICI) therapy alone. By identifying these subtle radiographic markers, Onc.AI equips oncologists with enhanced information to inform personalized treatment strategies for their patients.

The support from the NCI through this SBIR grant signifies a strong belief in the potential of AI technology to transform clinical practice. Onc.AI is committed to validating its AI-based decision support system in practical clinical environments to expand its applicability and efficacy, ultimately leading to improved patient outcomes.

Expert Insights on the Partnership

“Onc.AI’s technology has significant potential in the management of patients with metastatic Non-Small Cell Lung Cancer. I am thrilled for Ohio State to participate in this study aimed at evaluating clinical utility prospectively,” stated Dwight Owen, MD, MSc, thoracic medical oncologist at The James Comprehensive Cancer Center at The Ohio State University.

Echoing this sentiment, Petr Jordan, Chief Technical Officer of Onc.AI, expressed gratitude for the NCI's recognition: “We are excited about the progress we have made so far, and this grant enables us to refine our technology further” He added that this financial boost could facilitate the exploration of additional applications for their foundational deep learning radiomics biomarker technology.

About Onc.AI

Onc.AI is a forward-thinking, privately held digital health company striving to revolutionize oncology through its precision clinical management platform. Founded with the mission to advance predictive modeling for patient responses to PD-(L)1 immunotherapy, Onc.AI aims to develop a first-in-class radiomic solution that reduces unpredictability in treatment responses and enhances patient outcomes while optimizing costs for healthcare systems.

Frequently Asked Questions

What is the purpose of the $2 million grant awarded to Onc.AI?

The grant will support the further development and clinical validation of Onc.AI’s AI-based clinical decision support system for treating metastatic NSCLC.

What technology does Onc.AI utilize for cancer treatment?

Onc.AI uses deep learning to analyze imaging data, allowing for improved predictions regarding patient responses to treatment.

How does the grant impact Onc.AI's research initiatives?

The funding will enable Onc.AI to conduct a multi-institutional clinical study and further validate their AI technologies in real-world clinical settings.

What is the significance of the ASCO meeting for Onc.AI?

The ASCO meeting was significant for Onc.AI as they presented successful outcomes demonstrating their innovative clinical decision support capabilities.

Who are the key experts involved in the Onc.AI study?

Experts like Dwight Owen, MD, MSc, from The James Comprehensive Cancer Center are participating in evaluating the clinical utility of Onc.AI's technology.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

IEHP's Wellness Center Launch Faces Delay in California

Updated Category News Views 104

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 153

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 211

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 166

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 158

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 0

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 249

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 281

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 139

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading

Top 5 Most Recently Viewed Articles

BlueLinx Expands Its Reach with New Portland Distribution Hub

Updated Category News Views 147

BlueLinx Unveils New Distribution Center in Portland BlueLinx Holdings Inc. (NYSE: BXC) has officially opened a greenfield distribution center in Portland, enhancing its operational footprint in the Pacific Northwest. This facility is a significant addition to the company’s distribution capabilities, as it strategically positions BlueLinx to serve the growing demands of...

Continue Reading
IBA Partners with China Gold to Advance X-ray Technological Growth

Updated Category News Views 255

Strategic Partnership for Industry Advancement In a significant move for the irradiation processing industry, IBA (Ion Beam Applications S.A., EURONEXT) has joined forces with China Gold Irradiation (CGI), the premier irradiation service provider in China. This collaboration is set to elevate the standards of irradiation services by incorporating advanced X-ray...

Continue Reading
Amerant Bank and Partners Generate Support for Local Charity

Updated Category News Views 189

Generous Collaboration: Amerant Bank's Community Impact In a heartwarming display of community spirit, Amerant Bank has partnered with Sedano’s Supermarkets and Fresco y Más to make a significant difference in the lives of underserved children and families. The culmination of their efforts was marked by a grand check presentation to Centro Mater, a renowned...

Continue Reading
Mediar Therapeutics Advances Phase 2 Trial for Rare Lung Disease

Updated Category News Views 123

Mediar Therapeutics Initiates Phase 2 WISPer Trial Mediar Therapeutics, Inc., a pioneering clinical-stage biotechnology company, has reached a major milestone by dosing the first patient in its Phase 2 WISPer clinical trial. This trial focuses on evaluating MTX-463, a first-in-class therapy designed to combat idiopathic pulmonary fibrosis (IPF). The primary goal of this...

Continue Reading
Chime Biologics and Waterstone Unite for ADC Innovation

Updated Category News Views 242

Chime Biologics and Waterstone Forge a New Path in ADC Development Chime Biologics and Waterstone Pharmaceuticals have officially announced a strategic partnership designed to enhance the capabilities and efficiencies within the Antibody-Drug Conjugate (ADC) industry. By combining their expertise, both companies aim to provide integrated services that boost the...

Continue Reading